2022 Acetaminophen Concept Stocks are:
1, Fengyuan Pharmaceuticals: in the third quarter of 2022, the company realized total revenue of 968 million, gross profit margin of 27.98%, and earnings per share of 0.12 yuan.
Subsidiary Likang Pharmaceutical production capacity of 5,000 tons, the company's main business mainly consists of preparations, APIs, health care and commercial logistics four major segments: preparations segment in the chemical preparation of the main at the same time, and actively carry out cooperation with various key scientific research institutes and universities, the development of the new generation of bio-innovation of medicines, and actively to the transformation and development of biological preparations. In terms of APIs, through upgrading of production equipment and investment in high technology, the company has increased the market share of paracetamol, cefpirome, ceftriaxone, cefminox and DC series APIs, and has a number of API reserve projects, aiming to become an advanced API production base in China. Holding subsidiary Likang Pharmaceutical.
In the last seven trading days, Fengyuan Pharmaceuticals rose 11.16%, the highest price of 14.16 yuan, the total market value rose 608 million yuan, up 27.26% in 2022.
2, Renhe Pharmaceuticals: 2022 Q3 quarterly report shows that Renhe Pharmaceuticals Inc. achieved total revenue of 1.285 billion, gross margin of 34.93%, and earnings per share of $0.11.
In the last 7 days Renhe Pharmaceuticals shares rose 14.46%, 2022 shares fell -13.02%, the highest price of $8.49, the market capitalization of 11.717 billion.
3, CGC: In the third quarter of 2022, the company realized total revenue of $525 million, gross margin of 62.62%, and earnings per share of $0.01.
In the last 7 trading days, Zhongguancun fell 1.01%, the highest price of $6.94, the total market capitalization fell 52.7189 million yuan, down 1.01%.